Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
'Here we go again': Businesses grapple with fuel costs - 2Sahel coups push Africa to top of global democratic declines, report finds
- 3Nature carves colossal snowman in Siberia | Space photo of the day for Jan. 2, 2026
- 4Boeing's troubled capsule won't carry astronauts on next space station flight
- 5Artemis 2 astronauts are about to see one of the rarest skywatching sights of all — a solar eclipse from beyond the moon
- This St Nick Truly Can Advise How To Drink And Hack Your Headache
- From Representative to Business visionary: Private issue Victories
- As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated
- Ten Awesome Authentic Realities That Will Leave You Interested
- Curl Up With Some Hot Chocolate And Watch Mighty Car Mods Explore Japan In A Honda City Turbo II
- 'We need everyone,' wounded reservist urges Knesset panel to advance haredi draft law
- How did Hugh Jackman nail his latest role? Sequins, tighty-whities and embracing 'zero embarrassment.'
- Rediscovering Imagination in Adulthood: Individual Creative Excursions
- Radiated Tortoise Faces Rapid Decline in Madagascar
